Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on (S) CHBE. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN101392225A reveals a recombinant yeast route for high-purity (S)-CHBE, offering significant cost reduction in API manufacturing and robust supply chain scalability.
Patent CN103255183B details enzymatic asymmetric reduction for high-purity intermediates. Offers significant cost reduction and supply chain reliability for statin synthesis.
Patent CN112680425B reveals a novel alcohol dehydrogenase mutant for producing high-purity (S)-CHBE. This biocatalytic route offers significant cost reduction and supply chain reliability for statin manufacturing.
Patent CN104651292A reveals high-purity S-CHBE synthesis via recombinant E. coli. Achieves 100% conversion and 99.4% ee for scalable pharmaceutical intermediates.
Patent CN112143688A reveals a novel recombinant E. coli strain for high-purity (S)-CHBE production, offering significant cost reduction in API manufacturing.
Patent CN101392225B details a recombinant yeast method for high-purity statin intermediates, offering significant cost reduction in API manufacturing and supply chain reliability.
Patent CN103589665A reveals a novel Rhodococcus qingshengii strain for high-purity (S)-CHBE production, offering significant cost reduction in API manufacturing.
Patent CN1778889A details high-purity S-CHBE production via Aureobasidium pullulans. This method offers significant cost reduction and supply chain reliability for global buyers.
Patent CN103589665B reveals Rhodococcus qingshengii strain for high-purity (S)-CHBE production. Offers mild conditions and cost reduction in pharmaceutical intermediate manufacturing.
Patent CN101319236A details a green biocatalytic method for chiral alcohols using ionic liquids. Achieve high purity and cost reduction in pharma intermediate manufacturing with scalable processes.